In a nutshell This study investigated whether the omission of vincristine (Oncovin) from the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) regimen affects survival in patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that omitting vincristine does not affect survival in these patients. Some background...
Read More
In a nutshell This study investigated the long-term risk of cardiovascular mortality (death due to heart and blood vessel disease) among lymphoma survivors, compared to the general population. This study concluded that lymphoma survivors have a higher cardiovascular mortality risk compared to the general population. Some background Advances in...
Read More
Prior to the 20th century, most people lived about 47 years in the developed world because of infectious diseases. In 1940, the first use of penicillin to treat infectious diseases occurred and penicillin became available in 1945 to the general public. Science and research conducted throughout the 1950s, 60s, and 70s, created more antibiotics so that life...
Read More
In a nutshell This study evaluated the impact of rituximab (Rituxan) treatment on the risk of lymphoma transformation (development of aggressive lymphoma) in patients with follicular lymphoma (FL). They concluded that this risk can be significantly reduced by the use of first-line (primary treatment) rituximab. Some background FL is the second most...
Read MoreIn a nutshell This study investigated the occurrence and impact of bone loss in adult patients with lymphoma and leukemia. This study concluded that these patients have significant bone loss compared to the general population. Some background Bone loss is a known consequence of many cancers and their treatments. In healthy adults, bone loss is...
Read More
In a nutshell This study evaluated the safety and effectiveness of first-line (primary treatment) BR (bendamustine, rituximab) in frail elderly patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that the BR treatment showed promising effectiveness in these patients. Some background DLBCL is the most common type of...
Read More
In a nutshell This study investigated the outcomes of pretreated patients with relapsed (cancer recurrence) or refractory (does not respond to treatment) primary mediastinal large B-cell lymphoma (PMBCL) after second-line therapy and stem cell transplant (SCT). The study concluded that this treatment strategy was effective in most patients. Some...
Read More
When I think of vaccines, I think of the MMRV (measles, mumps, rubella and varicella) vaccines which help our bodies establish immunity against diseases that used to kill. Now, there are vaccines being created for cancer. The rise of cancer vaccines According to Dr. Nora Disis, an oncologist and researcher in cancer vaccines at the University of...
Read More
In a nutshell This study investigated the effectiveness of rituximab (Rituxan) maintenance therapy (treatment that is meant to help a primary treatment succeed) in patients with mantle cell lymphoma. The study concluded that this therapy improved survival outcomes in these patients after stem cell transplantation. Some background Chemoimmunotherapy is...
Read More
In a nutshell This study evaluated the safety and effectiveness of venetoclax (Venclexta) plus BR (bendamustine, rituximab) in patients with relapsed or refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL). This study concluded that this treatment was tolerated and showed promising effectiveness in these patients. Some...
Read More
In a nutshell This study evaluated the significance of the albumin to globulin ratio in pretreated patients with diffuse large B-cell lymphoma. The study concluded that this ratio was useful for predicting treatment outcomes in these patients. Some background R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is the most...
Read MoreIn a nutshell This article reviewed the outcomes and side effects associated with maintenance therapies for diffuse large B-cell lymphoma and mantle cell lymphoma. Some background After initial treatment, patients with diffuse large B-cell lymphoma (DLBCL) may have disease progression within 1 to 2 years. Patients with mantle cell lymphoma (MCL) may...
Read More
